Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia
Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia
复制标题
DOI：
10.1016/j.atherosclerosis.2010.10.023
复制
发表时间：
2011-01-01
期刊：
影响因子：
5.3
通讯作者：
Shin, Eak Kyun
中科院分区：
文献类型：
--
作者：
Koh, Kwang Kon;Quon, Michael J.;Shin, Eak Kyun
Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles.Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks.Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-alpha by 6 +/- 3% (P = 0.014) and hsCRP from 1.10 to 0.90 mg/l (P = 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 +/- 4% (P = 0.001), insulin sensitivity by 4 +/- 1% (as assessed by QUICKI, P = 0.009), and decreased plasma levels of leptin and resistin by 4 + 7% (P = 0.022) and 10 +/- 3% (P = 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r = 0.279, P = 0.043) or leptin (r = -0.280, P = 0.042).Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
